Lenalidomida Qilu (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate preference, leading to the degradation of transcription factors such as Ikaros and Aiolos. The result is immunomodulation, inhibition of new blood‑vessel formation, and direct anti‑tumor activity against malignant cells.

The specific dose of Lenalidomida Qilu is individualized by the treating physician based on the patient’s diagnosis, disease stage, renal function, and concurrent therapies. Only a qualified healthcare professional should determine the appropriate dosing schedule.

Lenalidomida Qilu is classified as Pregnancy Category X, meaning it is known to cause fetal harm and is contraindicated during pregnancy. Women of childbearing potential must use effective contraception. The drug is also not recommended while breastfeeding because it may pass into breast milk and affect the infant.

To request Lenalidomida Qilu, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory agent, and pomalidomide, a newer IMiD. Lenalidomide generally offers a more favorable safety profile than thalidomide, especially regarding peripheral neuropathy, while providing comparable anti‑myeloma efficacy. Compared with pomalidomide, lenalidomide is often used earlier in treatment sequences and has a broader indication set.

Lenalidomida Qilu should be stored at or below 25 °C (77 °F) in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink. Ensure the container is tightly closed when not in use.

Lenalidomida Qilu is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water. Patients should follow the exact schedule provided by their healthcare professional and not alter the dosing interval without medical advice.

The most critical risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Secondary primary malignancies have also been reported. Patients should promptly report fever, unusual bruising, shortness of breath, or sudden leg pain.

Lenalidomida Qilu is contraindicated in pregnant women and in individuals with known hypersensitivity to lenalidomide or any excipients in the tablet. Caution is advised for patients with severe renal impairment, uncontrolled infections, or a history of thromboembolic events unless appropriate prophylaxis is in place.